Dr. Nermin Gerges is the General Manager at Aspire, where she applies her academic and industry experience to support the mission of providing customized, comprehensive services that drive cellular therapies from conception to clinical translation and commercialization. Some of her day-to-day duties include overseeing operations, facilities, production as well as quality control and quality assurance requirements in manufacturing and fostering opportunities for business development and contract partnerships in Aspire’s different development and manufacturing services.
Prior to joining Aspire, Dr. Gerges’ work spanned clinical laboratory, research and analytical development, CMC writing and clinical manufacturing. Her experience in cellular therapies goes back to her contributions at Moffit Cancer Center as well as IOVANCE Biotherapeutics, where she developed, optimized, scaled-up and streamlined several processes for manufacture of T-cell cancer cellular therapies for clinical manufacture and commercial viability. She further led training and transfer of the technologies to the manufacturing team for clinical manufacture and contributed in the preparation of CMC regulatory submissions.
Dr. Gerges received her MSc in Biotechnology from Johns Hopkins University and her PhD in Molecular Biology and Genetics from Wayne State University. She is a member of the International Society for Cell & Gene Therapies (ISCT), the American Society for Clinical Pathology (ASCP) and the Regulatory Affairs Professional Society (RAPS).